The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion

Haematologica

Volumn 97, Issue 5, 2012, Pages 771-779

  Biberacher, Viola ^a   Decker, Thomas ^a   Oelsner, Madlen ^a   Wagner, Michaela ^a   Bogner, Christian ^a   Schmidt, Burkhard ^b   Kreitman, Robert J ^c   Peschel, Christian ^a   Pastan, Ira ^c   zum Büschenfelde, Christian Meyer ^a   Ringshausen, Ingo ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Onkologie Onkologie Pasing   (Germany)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

B cell lymphoma; Bryostatin 1; CD22; CLL; Immunotoxin

Indexed keywords

ACTIN; BRYOSTATIN 1; CD22 ANTIGEN; IMMUNOTOXIN; IMMUNOTOXIN BL22; LIPOCORTIN 5; PROTEIN KINASE C BETA; PROTEIN KINASE C EPSILON; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL STRUCTURE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPHENOTYPING; MANTLE CELL LYMPHOMA; PROTEIN EXPRESSION; UPREGULATION;

ANTIBODIES; ANTIGENS, CD22; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRYOSTATINS; ENTEROTOXINS; HUMANS; IMMUNOTOXINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; LYMPHOMA, MANTLE-CELL; PROTEIN KINASE C; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84860589922     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.049155     Document Type: Article

References (41)

1. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-88.
2. Hallek M. Chronic lymphocytic leukemia (CLL): first-line treatment. Hematology Am Soc Hematol Educ Program. 2005:285-91.
3. Bosch F, Abrisqueta P, Villamor N, Terol MJ, Gonzalez-Barca E, Ferra C, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009;27(27): 4578-84.
4. Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC, FitzGerald DJ, Pastan I. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res. 2000;6(4):1476-87.
5. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapyresistant hairy-cell leukemia. N Engl J Med. 2001;345(4):241-7.
6. Decker T, Oelsner M, Kreitman RJ, Salvatore G, Wang QC, Pastan I, et al. Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. Blood. 2004;103 (7):2718-26.
7. Mutter R, Wills M. Chemistry and clinical biology of the bryostatins. Bioorg Med Chem. 2000;8(8):1841-60.
8. Thomas A, Pepper C, Hoy T, Bentley P. Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells. Leuk Lymphoma. 2004;45(5):997-1008.
9. Bellosillo B, Dalmau M, Colomer D, Gil J. Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells. Blood. 1997;89(9):3378-84.
10. Gomez-Angelats M, Cidlowski JA. Protein kinase C regulates FADD recruitment and death-inducing signaling complex formation in Fas/CD95-induced apoptosis. J Biol Chem. 2001;276(48):44944-52.
11. Kortmansky J, Schwartz GK. Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest. 2003;21(6):924-36.
12. Varterasian ML, Mohammad RM, Eilender DS, Hulburd K, Rodriguez DH, Pemberton PA, et al. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol. 1998;16(1):56-62.
13. Roberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, et al. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma. Clin Cancer Res. 2006;12(19): 5809-16.
14. al-Katib A, Mohammad RM, Dan M, Hussein ME, Akhtar A, Pettit GR, et al. Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Exp Hematol. 1993;21(1):61-5.
15. Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sanchez A, Martin-Saavedra M, et al. A sustained activation of PI3K/NFkappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia. 2004;18(8):1391-400.
16. Abrams ST, Lakum T, Lin K, Jones GM, Treweeke AT, Farahani M, et al. B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII. Blood. 2007;109(3):1193-201.
17. Holler C, Pinon JD, Denk U, Heyder C, Hofbauer S, Greil R, et al. PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKC beta as a therapeutic target in chronic lymphocytic leukemia. Blood. 2009;113(12):2791-4.
18. zum Buschenfelde CM, Wagner M, Lutzny G, Oelsner M, Feuerstacke Y, Decker T, et al. Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70. Leukemia.24(1):141-52.
19. Faul MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, Kahl A, et al. Acyclic N-(azacycloalkyl) bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. Bioorg Med Chem Lett. 2003;13(11):1857-9.
20. Parker PJ, Bosca L, Dekker L, Goode NT, Hajibagheri N, Hansra G. Protein kinase C (PKC)-induced PKC degradation: a model for down-regulation. Biochem Soc Trans. 1995;23(1):153-5.
21. Kang BS, French OG, Sando JJ, Hahn CS. Activation-dependent degradation of protein kinase C eta. Oncogene. 2000;19(37): 4263-72.
22. Varterasian ML, Mohammad RM, Shurafa MS, Hulburd K, Pemberton PA, Odriguez DH, et al. Phase II trial of bryostatin 1 in patients with relapsed low-grade non- Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res. 2000;6(3): 825-8.
23. Kitada S, Zapata JM, Andreeff M, Reed JC. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol. 1999;106(4):995-1004.
24. Tedder TF, Tuscano J, Sato S, Kehrl JH. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol. 1997;15:481-504.
25. Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non- Hodgkin's lymphoma. J Clin Oncol. 2006; 24(24):3880-6.
26. Cesano A, Gayko U. CD22 as a target of passive immunotherapy. Semin Oncol. 2003;30(2):253-7.
27. Dyer MJ, Fischer P, Nacheva E, Labastide W, Karpas A. A new human B-cell non- Hodgkin's lymphoma cell line (Karpas 422) exhibiting both t (14;18) and t(4;11) chromosomal translocations. Blood. 1990;75(3): 709-14.
28. Beckwith M, Longo DL, O'Connell CD, Moratz CM, Urba WJ. Phorbol esterinduced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines. J Natl Cancer Inst. 1990;82(6):501-9.
29. Winter JN, Variakojis D, Epstein AL. Phenotypic analysis of established diffuse histiocytic lymphoma cell lines utilizing monoclonal antibodies and cytochemical techniques. Blood. 1984;63(1):140-6.
30. Jadayel DM, Lukas J, Nacheva E, Bartkova J, Stranks G, De Schouwer PJ, et al. Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519). Leukemia. 1997; 11(1):64-72.
31. Bogner C, Dechow T, Ringshausen I, Wagner M, Oelsner M, Lutzny G, et al. Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression. Br J Haematol. 2010;148(1):99-109.
32. Jeon HJ, Kim CW, Yoshino T, Akagi T. Establishment and characterization of a mantle cell lymphoma cell line. Br J Haematol. 1998;102(5):1323-6.
33. O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001; 19(8):2165-70.
34. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1749-55.
35. Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol. 2003;21(16):3051-9.
36. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with Bcell malignancies. J Clin Oncol. 2005;23(27): 6719-29.
37. al-Katib A, Wang CY, McKenzie S, Clarkson BD, Koziner B. Phorbol ester-induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Am J Hematol. 1992; 40(4):264-9.
38. Lee HW, Smith L, Pettit GR, Smith JB. Bryostatin 1 and phorbol ester down-modulate protein kinase C-alpha and -epsilon via the ubiquitin/proteasome pathway in human fibroblasts. Mol Pharmacol. 1997;51 (3):439-47.
39. Pavlick AC, Wu J, Roberts J, Rosenthal MA, Hamilton A, Wadler S, et al. Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors. Cancer Chemother Pharmacol. 2009;64(4):803-10.
40. Grant S, Roberts J, Poplin E, Tombes MB, Kyle B, Welch D, et al. Phase Ib trial of bryostatin 1 in patients with refractory malignancies. Clin Cancer Res. 1998;4(3): 611-8.
41. Du X, Youle RJ, FitzGerald DJ, Pastan I. Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1. Mol Cell Biol. 2010;30(14):3444-52.